Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD

Clinical trial NCT07178249 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07178249
Sponsor: Guangzhou Jiayin Biotech Ltd
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Wet Age-related Macular Degeneration

Start date: 2025-10-16
Primary completion: 2028-02-28
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.